Re: Moxifloxacin should not be discounted in the treatment of bacterial meningitis.
Institute of Infection and Global Health, University of Liverpool, UK; National Institute for Health Research Health Protection Research Unit on Emerging and Zoonotic Infections, UK. Electronic address: fmcgill@liv.ac.uk.
Fiona
F
McGill
Division of Infection & Immunity, University College London, UK.
Robert S
RS
Heyderman
Institute of Infection and Global Health, University of Liverpool, UK; National Institute for Health Research Health Protection Research Unit on Emerging and Zoonotic Infections, UK; Walton Centre NHS Foundation Trust, Liverpool, UK.
Tom
T
Solomon
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D006801:Humans; D016920:Meningitis, Bacterial; D000077266:Moxifloxacin
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D000077266:Moxifloxacin